Gukasyan N

Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care.

Geller JA, Pacilio R, Downey AE +4

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones.

Goldy SP, Sepeda ND, Hilbert SN +6

Informed Consent in Psychedelic-Assisted Therapy.

Bradberry MM, Appelbaum PS, Gukasyan N

ArticleMDMA

Exploring Self-Reported Effects of Naturalistic Psychedelic Use Among Gender and Sexual Minorities: A Quantitative Survey Study.

Lancelotta R, DellaCrosse M, Quinn D +7

Europe PMC2025

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.

Yaden DB, Graziosi M, Owen AM +39

Europe PMC2025

ArticleKetamine

Ketamine and the Consequences of Positive Psychedelic Exceptionalism.

Verne ZJ, Gukasyan N, Zabinski J

Europe PMC2025

Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.

Wang E, Mathai DS, Gukasyan N +2

Beyond the numbers: reimagining healing with psychedelics for eating disorders.

Lafrance A, Spriggs MJ, Gukasyan N +1

Psilocybin in Bipolar II Study Provides Preliminary Data on Safety.

Yaden DB, Gukasyan N, Nayak SM

The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder.

Levin AW, Lancelotta R, Sepeda ND +6

Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.

O'Donnell KC, Anderson BT, Barrett FS +9

ArticlePsychedelics

What Is in a Name? The Many Meanings of "Psychedelic".

O'Donnell KC, Roberts DE, Ching THW +8

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.

Raison CL, Sanacora G, Woolley J +31

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use.

Gukasyan N, Griffiths RR, Yaden DB +2

Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series.

Gukasyan N, Narayan SK

On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression.

Gukasyan N

ArticlePsychedelics

Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms.

Nikolaidis A, Lancelotta R, Gukasyan N +3

Psychedelic-Assisted Therapy for People with Eating Disorders.

Gukasyan N, Schreyer CC, Griffiths RR +1

Europe PMC2022

ArticleMDMA

Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies.

Bradberry MM, Gukasyan N, Raison CL

Europe PMC2022

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

Gukasyan N, Davis AK, Barrett FS +4

Europe PMC2022

Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.

Nayak SM, Gukasyan N, Barrett FS +3

Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities.

Yaden DB, Johnson MW, Griffiths RR +6

PreprintPsilocybin

Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports

Nayak S, Gukasyan N, Barrett FS +3

Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.

Davis AK, Barrett FS, So S +3